A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial


Akman Demir G., Turkoglu R., Saip S., Yuceyar N., EFENDİ H. , TURAN Ö. F. , ...Daha Fazla

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.56, ss.253-257, 2019 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 56 Konu: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5152/npa.2017.20515
  • Dergi Adı: NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
  • Sayfa Sayıları: ss.253-257

Özet

Introduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.